Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
04:05pm, Friday, 20'th Feb 2026
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th A
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management
The London Company Small Cap Q4 2025 Performance And Trades
09:27am, Tuesday, 17'th Feb 2026
The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance G
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioede
Haemonetics (HAE) International Revenue Performance Explored
10:15am, Tuesday, 10'th Feb 2026
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
06:50am, Tuesday, 10'th Feb 2026
Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand
Chuck Royce's Strategic Moves: Significant Reduction in Haemonetics Corp
05:03pm, Monday, 09'th Feb 2026
Exploring the Fourth Quarter 2025 13F Filing Chuck Royce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insigh
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
10:40am, Monday, 09'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics Q3 Earnings Call Highlights
04:16am, Sunday, 08'th Feb 2026
Haemonetics (NYSE: HAE) management struck an upbeat tone on its fiscal third-quarter 2026 earnings call, highlighting "outsized" growth in its NexSys plasma platform and TEG hospital blood management
These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings
12:28pm, Friday, 06'th Feb 2026
Haemonetics Corporation (NYSE: HAE) reported upbeat earnings for its third quarter on Thursday.
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Friday, 06'th Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
10:36am, Friday, 06'th Feb 2026
HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
05:34pm, Thursday, 05'th Feb 2026
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
01:55pm, Thursday, 05'th Feb 2026
Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Pha
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say
10:31am, Thursday, 05'th Feb 2026
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics com
